Car-T and Bispecific Antibodies for Refractory Non-Hodgkin Lymphoma: Long-Term Safety and Autoimmune Sequelae. JOC [Internet]. 2025 Sep. 24 [cited 2026 Jan. 15];24(6s):805-20. Available from: https://carcinogenesis.com/index.php/JOC/article/view/1781